Comparison of M-TAPA and External Oblique Intercostal Block for Intraoperative Opioid Consumption in Laparoscopic Cholecystectomy (MTAPA-EOI)

September 20, 2026 updated by: İsmet Uluhan, Ankara Etlik City Hospital

Comparison of M-TAPA and External Oblique Intercostal Plane Block on Intraoperative Analgesia and Opioid Consumption Guided by Skin Conductance Algesimeter in Laparoscopic Cholecystectomy

This prospective, randomized, interventional study compares the effects of modified thoracoabdominal nerve block through perichondrial approach (M-TAPA) and external oblique intercostal plane block (EOI) on intraoperative analgesia and opioid consumption in patients undergoing elective laparoscopic cholecystectomy.

Eighty patients are randomized into two groups: the M-TAPA group and the EOI group. All patients receive standardized general anesthesia. Intraoperative analgesia is guided using the Skin Conductance Algesimeter (SCA), which reflects sympathetic nervous system activity by measuring fluctuations in skin conductance. The SCA parameter "peaks per second (PPS)" is used to assess nociceptive responses, and remifentanil infusion is titrated according to SCA values.

Patients assigned to the M-TAPA group receive bilateral ultrasound-guided M-TAPA block, while patients assigned to the EOI group receive bilateral ultrasound-guided external oblique intercostal plane block. In both groups, 20 mL of 0.25% bupivacaine is administered on each side.

Perioperative analgesia is standardized. All patients receive intravenous dexketoprofen toward the end of surgery. During postoperative follow-up, intravenous paracetamol is administered as rescue analgesia when the numeric rating scale (NRS) pain score is 4 or higher.

The primary outcome is the time-weighted average intraoperative remifentanil infusion rate (µg/kg/min). Secondary outcomes include total intraoperative remifentanil consumption, intraoperative hemodynamic parameters, SCA measurements, postoperative pain scores, time to first rescue analgesic requirement, rescue analgesic consumption, postoperative nausea and vomiting, and perioperative complications.

The study aims to compare the opioid-sparing and analgesic effects of M-TAPA and EOI under objective nociception-guided intraoperative analgesia.

Study Overview

Detailed Description

This prospective, randomized, interventional study compares modified thoracoabdominal nerve block through perichondrial approach (M-TAPA) and external oblique intercostal plane block (EOI) in patients undergoing elective laparoscopic cholecystectomy.

A total of 80 patients are randomized in a 1:1 ratio to either the M-TAPA group or the EOI group. Patients and postoperative outcome assessors are blinded to group allocation. The anesthesiologist performing the block is not blinded because of the nature of the procedures.

All patients receive standardized general anesthesia. Intraoperative analgesia is guided using the Skin Conductance Algesimeter (SCA), which reflects sympathetic activation through fluctuations in palmar skin conductance. The SCA-derived parameter "peaks per second (PPS)" is used as a real-time measure of nociceptive activity. Remifentanil is administered by continuous infusion and titrated according to SCA values to maintain the predefined target range.

Patients randomized to the M-TAPA group receive bilateral ultrasound-guided modified thoracoabdominal nerve block through perichondrial approach. Patients randomized to the EOI group receive bilateral ultrasound-guided external oblique intercostal plane block. In both groups, 20 mL of 0.25% bupivacaine is administered on each side.

Intraoperative data include heart rate, mean arterial pressure, SCA-derived PPS values, and remifentanil infusion rates. The primary outcome is the time-weighted average intraoperative remifentanil infusion rate (µg/kg/min). Secondary outcomes include total intraoperative remifentanil consumption, frequency of SCA values outside the predefined target range, postoperative pain intensity assessed using the numeric rating scale (NRS), time to first rescue analgesic requirement, rescue analgesic consumption during the first 24 postoperative hours, postoperative nausea and vomiting, and perioperative complications.

Perioperative analgesia is standardized in both groups. All patients receive intravenous dexketoprofen toward the end of surgery. During postoperative follow-up, intravenous paracetamol is administered as rescue analgesia when the NRS pain score is 4 or higher.

The study is designed to determine whether M-TAPA and EOI differ in their effects on intraoperative opioid requirements and postoperative analgesia when intraoperative nociception is objectively monitored using the Skin Conductance Algesimeter.

Study Type

Interventional

Enrollment (Actual)

80

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Yenimahalle
      • Ankara, Yenimahalle, Turkey (Türkiye)
        • Ankara etlik city hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients aged 18-80 years
  • ASA physical status I-III
  • Scheduled for elective laparoscopic cholecystectomy under general anesthesia
  • Ability to provide written informed consent

Exclusion Criteria:

  • Patient refusal
  • Known allergy to local anesthetics
  • Chronic opioid use or opioid dependence
  • Neurological or psychiatric disorders affecting pain perception
  • Use of medications affecting autonomic nervous system activity, such as beta-blockers
  • Infection at the injection site
  • Coagulopathy or anticoagulant therapy
  • Pregnancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: M-TAPA Group

Patients assigned to this arm received bilateral modified thoracoabdominal nerve block through perichondrial approach (M-TAPA) for perioperative analgesia during laparoscopic cholecystectomy.

Patients received bilateral ultrasound-guided modified thoracoabdominal nerve block through perichondrial approach (M-TAPA). A total of 20 mL of 0.25% bupivacaine was administered on each side for perioperative analgesia during laparoscopic cholecystectomy.

Other Names:
  • M-TAPA
Active Comparator: EOI Group

Patients assigned to this arm received bilateral external oblique intercostal plane block (EOIPB) for perioperative analgesia during laparoscopic cholecystectomy.

Patients received bilateral ultrasound-guided external oblique intercostal plane block (EOI). A total of 20 mL of 0.25% bupivacaine was administered on each side for perioperative analgesia during laparoscopic cholecystectomy.

Other Names:
  • EOI

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time-Weighted Mean Intraoperative Remifentanil Infusion Rate
Time Frame: Intraoperative period (from induction to end of surgery)

The time-weighted mean intraoperative remifentanil infusion rate will be calculated throughout the surgical period and expressed as micrograms per kilogram per minute (µg/kg/min) based on continuous infusion data.

Intraoperative period (from induction to end of surgery)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Postoperative Pain Scores Assessed by Numeric Rating Scale
Time Frame: 0, 2, 4, 6, 12, and 24 hours postoperatively

Postoperative pain intensity will be assessed using the Numeric Rating Scale (NRS), ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. Higher scores indicate worse pain. Assessments will be performed at rest and during movement.

0, 2, 4, 6, 12, and 24 hours postoperatively
Time to First Analgesic Requirement
Time Frame: Within 24 hours postoperatively

Time to First Analgesic Requirement

Within 24 hours postoperatively
Rescue Analgesic Consumption
Time Frame: First 24 hours postoperatively

Total amount of rescue analgesic (dexketoprofen) administered within the first 24 hours postoperatively.

First 24 hours postoperatively
Mean Arterial Pressure
Time Frame: Intraoperative period

Mean arterial pressure (MAP), expressed in mmHg, will be recorded intraoperatively and compared with baseline values.

Intraoperative period
Heart Rate
Time Frame: Intraoperative period

Heart rate, expressed as beats per minute, will be recorded intraoperatively and compared with baseline values.

Intraoperative period
Skin Conductance Algesimeter(SCA)
Time Frame: Intraoperative period

Skin Conductance Algesimeter (SCA) peaks per second (PPS) values recorded intraoperatively to assess nociceptive responses.

Intraoperative period
Postoperative Nausea and Vomiting (PONV)
Time Frame: First 24 hours postoperatively

Incidence of postoperative nausea and vomiting within the first 24 hours after surgery.

First 24 hours postoperatively

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 15, 2026

Primary Completion (Actual)

August 31, 2026

Study Completion (Actual)

September 1, 2026

Study Registration Dates

First Submitted

May 5, 2026

First Submitted That Met QC Criteria

May 15, 2026

First Posted (Actual)

May 19, 2026

Study Record Updates

Last Update Posted (Actual)

September 23, 2026

Last Update Submitted That Met QC Criteria

September 20, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be shared in accordance with institutional policies

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe